MA43001A - Cannabidiol et hu-211 pour le traitement d'une lésion cérébrale traumatique - Google Patents

Cannabidiol et hu-211 pour le traitement d'une lésion cérébrale traumatique

Info

Publication number
MA43001A
MA43001A MA043001A MA43001A MA43001A MA 43001 A MA43001 A MA 43001A MA 043001 A MA043001 A MA 043001A MA 43001 A MA43001 A MA 43001A MA 43001 A MA43001 A MA 43001A
Authority
MA
Morocco
Prior art keywords
cannabidiol
treatment
brain injury
traumatic brain
traumatic
Prior art date
Application number
MA043001A
Other languages
English (en)
Inventor
David A Schrader
Original Assignee
Impact Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Impact Biosciences Corp filed Critical Impact Biosciences Corp
Publication of MA43001A publication Critical patent/MA43001A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA043001A 2015-10-16 2016-10-17 Cannabidiol et hu-211 pour le traitement d'une lésion cérébrale traumatique MA43001A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562242457P 2015-10-16 2015-10-16

Publications (1)

Publication Number Publication Date
MA43001A true MA43001A (fr) 2021-04-07

Family

ID=58518045

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043001A MA43001A (fr) 2015-10-16 2016-10-17 Cannabidiol et hu-211 pour le traitement d'une lésion cérébrale traumatique

Country Status (12)

Country Link
US (1) US20180303793A1 (fr)
EP (1) EP3362067A4 (fr)
JP (1) JP2018534362A (fr)
KR (1) KR20180094856A (fr)
CN (1) CN108289884A (fr)
AU (1) AU2016337507B2 (fr)
CA (1) CA3002036A1 (fr)
IL (1) IL258629A (fr)
MA (1) MA43001A (fr)
MX (1) MX2018004632A (fr)
RU (1) RU2701565C1 (fr)
WO (1) WO2017066744A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL291874A (en) * 2019-10-04 2022-06-01 Incannex Healthcare Ltd Preparations and methods for the treatment or prevention of traumatic brain injury
US20220280447A1 (en) * 2021-03-05 2022-09-08 Health Via Modern Nutrition Inc. Compositions and methods for improving brain function

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69936640D1 (de) * 1998-04-21 2007-09-06 Us Health Cannabinoiden als antioxidantien und neuroschützende mittel
IL145209A0 (en) * 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
GB2434312B (en) * 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
WO2008001369A1 (fr) * 2006-06-27 2008-01-03 Pharmos Corporation Utilisation d'agonistes des récepteurs cb2 pour améliorer la neurogenèse
EP2708262A3 (fr) * 2007-10-12 2014-04-23 The Government of the U.S.A. as represented by The Secretary of the dept. of Health & Human Services Applications thérapeutiques d'inhibiteurs d'hydrolase d'amide d'acide gras
MX355972B (es) * 2009-11-19 2018-05-07 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Canfenos arilados novedosos, procesos para su preparacion y usos.
UA108233C2 (uk) * 2010-05-03 2015-04-10 Модулятори активності гідролази амідів жирних кислот
WO2011137511A1 (fr) * 2010-05-05 2011-11-10 Waratah Pharmaceuticals Inc. Composés, compositions et procédés de traitement de lésions du système nerveux central
US8895537B2 (en) * 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US9149537B2 (en) * 2010-11-04 2015-10-06 Board Of Regents Of The University Of Nebraska Compositions and methods for the treatment of traumatic brain injury
US10058530B2 (en) * 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
WO2014108899A1 (fr) * 2013-01-08 2014-07-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Composés de cbd fluorés, compositions les contenant et utilisations
KR20170013890A (ko) * 2014-05-06 2017-02-07 노쓰웨스턴유니버시티 Nmdar 조절 화합물의 조합물

Also Published As

Publication number Publication date
RU2701565C1 (ru) 2019-09-30
KR20180094856A (ko) 2018-08-24
CN108289884A (zh) 2018-07-17
AU2016337507B2 (en) 2019-09-19
AU2016337507A1 (en) 2018-05-31
EP3362067A1 (fr) 2018-08-22
US20180303793A1 (en) 2018-10-25
EP3362067A4 (fr) 2019-07-17
MX2018004632A (es) 2018-11-09
CA3002036A1 (fr) 2017-04-20
JP2018534362A (ja) 2018-11-22
IL258629A (en) 2018-06-28
WO2017066744A1 (fr) 2017-04-20

Similar Documents

Publication Publication Date Title
MA45192A (fr) Traitement d'association
MA49144A (fr) Polythérapies pour le traitement du cancer
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA47310A (fr) Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
MA55629A (fr) Compositions d'anticorps pour le traitement de tumeurs
MA42420A (fr) Vaccins pour le traitement et la prévention du cancer
MA50482A (fr) Dérivés cyclisés de sulfamoylarylamide et leur utilisation comme médicaments pour le traitement de l'hépatite b
MA40867A (fr) Méthodes pour le traitement d'infections virales à filoviridae
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
MA41028A (fr) Méthodes et formulations pour le traitement de pathologies oculaires vasculaires
MA44699A (fr) Association d'un antagoniste du pd-1 et d'un oligonucléotide cpg du type c pour le traitement du cancer
MA41449A (fr) Polythérapies pour le traitement de cancers
MA47719A (fr) Esketamine pour le traitement de la dépression
MA48637A (fr) Polythérapies pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
MA43000A (fr) Polythérapie pour le traitement de tumeurs malignes
MA54925A (fr) Compositions pour le traitement de troubles acido-basiques
FR3032353B1 (fr) Composition pharmaceutique et dispositif pour le traitement de la douleur
MA42953A (fr) Composés et compositions pour le traitement de troubles oculaires
MA42999A (fr) Polythérapie pour le traitement de malignités
MA45406A (fr) Inhibiteurs d'ezh2 pour traiter le cancer
MA43170A (fr) Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer